Castle Biosciences (NASDAQ:CSTL) Updates FY 2021 Earnings Guidance

Castle Biosciences (NASDAQ:CSTL) updated its FY 2021 earnings guidance on Tuesday. The company provided earnings per share guidance of $- for the period. The company issued revenue guidance of $80 million-83 million, compared to the consensus revenue estimate of $79.84 million.

Several brokerages have weighed in on CSTL. Zacks Investment Research raised Castle Biosciences from a sell rating to a hold rating in a report on Monday, May 10th. Robert W. Baird reissued a buy rating and set a $73.00 price objective on shares of Castle Biosciences in a report on Thursday, May 13th. Finally, Lake Street Capital began coverage on Castle Biosciences in a report on Friday, April 30th. They set a buy rating and a $94.00 price objective for the company. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. Castle Biosciences currently has a consensus rating of Buy and an average target price of $80.29.

Shares of CSTL traded down $0.86 on Friday, hitting $70.36. The company’s stock had a trading volume of 10,542 shares, compared to its average volume of 289,573. The business has a fifty day moving average of $63.70. Castle Biosciences has a fifty-two week low of $34.72 and a fifty-two week high of $107.69. The stock has a market capitalization of $1.76 billion, a price-to-earnings ratio of -100.31 and a beta of 0.42.

Castle Biosciences (NASDAQ:CSTL) last issued its quarterly earnings data on Sunday, May 9th. The company reported ($0.17) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.23) by $0.06. Castle Biosciences had a negative return on equity of 4.74% and a negative net margin of 22.24%. The business had revenue of $22.81 million during the quarter, compared to analyst estimates of $16.66 million. During the same period in the previous year, the firm earned $0.03 EPS. Castle Biosciences’s quarterly revenue was up 30.9% compared to the same quarter last year. As a group, analysts predict that Castle Biosciences will post -0.92 earnings per share for the current fiscal year.

In other Castle Biosciences news, Director David S. Kabakoff sold 10,000 shares of the stock in a transaction on Friday, March 19th. The stock was sold at an average price of $66.17, for a total transaction of $661,700.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director David S. Kabakoff sold 120,000 shares of the stock in a transaction on Tuesday, March 16th. The stock was sold at an average price of $63.74, for a total value of $7,648,800.00. The disclosure for this sale can be found here. In the last three months, insiders sold 374,137 shares of company stock valued at $24,818,071. 15.40% of the stock is currently owned by insiders.

Castle Biosciences Company Profile

Castle Biosciences, Inc, a commercial-stage dermatological cancer company, focuses to provide diagnostic and prognostic solutions for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify high-risk patients with stage I and II melanomas based on biological information from 31 genes within their tumor tissue.

Recommended Story: What is the Coverage Ratio?

Earnings History and Estimates for Castle Biosciences (NASDAQ:CSTL)

Receive News & Ratings for Castle Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Castle Biosciences and related companies with's FREE daily email newsletter.